Table 3.
MICs against 126 clinical NTS isolates and study isolates S129-42 and S1-9210131a
| Drugb | Nontyphoid Salmonella isolates |
MIC (μg/ml) |
|||
|---|---|---|---|---|---|
| MIC50 (μg/ml) | MIC90 (μg/ml) | % susceptiblea | S129-42 | S1-9210131 | |
| AMP | 32 | >512 | 48.8 | >256 | >256 |
| CHL | 8 | >256 | 53.2 | 256 | 64 |
| CIP | <0.125 | 2 | 88.9 | <0.125 | >32 |
| CRO | <1 | 4 | 88.1 | 0.062 | 12 |
| SXT | 0.25/4.75 | >32/608 | 69.8 | 0.5 | >16 |
| DOR | 0.062 | 0.062 | 100 | 0.062 | 0.062 |
| EPT | <0.015 | <0.015 | 100 | <0.015 | <0.015 |
| IMI | 0.5 | 1 | 100 | 0.5 | 0.25 |
| MEM | 0.031 | 0.031 | 100 | 0.031 | 0.031 |
a
Susceptibility was determined by the updated breakpoints recommended in the M100-S21 CLSI document (8).
b
AMP, ampicillin; CRO, ceftriaxone; CIP, ciprofloxacin; CHL, chloramphenicol; SXT, trimethoprim-sulfamethoxazole; EPT, ertapenem; MEM, meropenem; IMI, imipenem; and DOR, doripenem.